BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1177 related articles for article (PubMed ID: 24960469)

  • 1. Evaluation and medical management of kidney stones in children.
    Tasian GE; Copelovitch L
    J Urol; 2014 Nov; 192(5):1329-36. PubMed ID: 24960469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Functional evaluation in patients with kidney calculi].
    Stojimirović B
    Srp Arh Celok Lek; 1998; 126(9-10):394-8. PubMed ID: 9863414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
    Lotan Y; Buendia Jiménez I; Lenoir-Wijnkoop I; Daudon M; Molinier L; Tack I; Nuijten MJ
    BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prevention of kidney stones: an update.
    Frassetto L; Kohlstadt I
    Am Fam Physician; 2011 Dec; 84(11):1234-42. PubMed ID: 22150656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of recurrent nephrolithiasis.
    Goldfarb DS; Coe FL
    Am Fam Physician; 1999 Nov; 60(8):2269-76. PubMed ID: 10593318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric urinary stone disease--does age matter?
    Kalorin CM; Zabinski A; Okpareke I; White M; Kogan BA
    J Urol; 2009 May; 181(5):2267-71; discussion 2271. PubMed ID: 19296968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of kidney stones: AUA guideline.
    Pearle MS; Goldfarb DS; Assimos DG; Curhan G; Denu-Ciocca CJ; Matlaga BR; Monga M; Penniston KL; Preminger GM; Turk TM; White JR;
    J Urol; 2014 Aug; 192(2):316-24. PubMed ID: 24857648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical approach to adults.
    Monk RD
    Semin Nephrol; 1996 Sep; 16(5):375-88. PubMed ID: 8890394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of nephrolithiasis: where is the evidence from clinical trials?
    Pachaly MA; Baena CP; Carvalho Md
    J Bras Nefrol; 2016 Mar; 38(1):99-106. PubMed ID: 27049371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones.
    Alvarez Arroyo MV; Traba ML; Rapado A
    Urol Int; 1992; 48(3):342-6. PubMed ID: 1589930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study.
    Borghi L; Meschi T; Amato F; Briganti A; Novarini A; Giannini A
    J Urol; 1996 Mar; 155(3):839-43. PubMed ID: 8583588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum nutrition for kidney stone disease.
    Heilberg IP; Goldfarb DS
    Adv Chronic Kidney Dis; 2013 Mar; 20(2):165-74. PubMed ID: 23439376
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 59.